Ultragenyx Pharmaceutical develops and commercializes therapies for rare and ultra-rare genetic diseases, often with limited or no prior treatment options. Its portfolio spans approved products and a pipeline of biologics, small molecules and gene therapies targeting metabolic, bone and other rare disorders. The company focuses on specialty rare-disease markets rather than broad primary-care pharmaceuticals.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 167 | — | -115 | — |
| Q3 2025 | 159.9 | — | -180.4 | — |
| Q4 2025 | 207.3 | — | -128.6 | — |
| Q1 2026 | 136 | — | -185 | — |
| Q2 2026 | 214 | 28.1% | -92 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Certara, Inc. (CERT), Keel Infrastructure Corp. (KEEL), Westamerica Bancorporation (WABC), Absci Corporation (ABSI), Amalgamated Financial Corp. (AMAL), Arhaus, Inc. (ARHS)